Merck and Threshold Announce Global Agreement to Co-Develop and Commercialize Phase III Hypoxia-Targeted Drug TH-302
Phase III soft tissue sarcoma trial ongoing; randomized Phase II pancreatic cancer trial expected to report in February 2012
06-Feb-2012 -
Merck KGaA announced that a global agreement was signed with Threshold Pharmaceuticals, Inc. to co-develop and commercialize TH-302, Threshold’s small molecule hypoxia-targeted drug. TH-302 is currently being investigated in a global Phase III clinical trial in patients with soft tissue sarcoma, ...
Merck
pancreatic cancer
phase III studies
+1